

Michael T Collins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8941325/publications.pdf>

Version: 2024-02-01

141
papers

9,538
citations

34493

54
h-index

45040

94
g-index

144
all docs

144
docs citations

144
times ranked

6165
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibrous dysplasia animal models: A systematic review. <i>Bone</i> , 2022, 155, 116270.	1.4	6
2	Calvarial hyperostosis in primary hyperparathyroidism and other settings of increased cAMP signalling. <i>Lancet, The</i> , 2022, 399, 956.	6.3	3
3	Skeletal and extraskeletal disorders of biomineralization. <i>Nature Reviews Endocrinology</i> , 2022, 18, 473-489.	4.3	25
4	Infgratinib Reduces Fibroblast Growth Factor 23 (<sc>FGF23</sc>) and Increases Blood Phosphate in <sc>Tumor-Induced</sc> Osteomalacia. <i>JBMR Plus</i> , 2022, 6, .	1.3	7
5	Tumor-Induced Osteomalacia. <i>Calcified Tissue International</i> , 2021, 108, 128-142.	1.5	87
6	Optic disc edema in fibrous dysplasia/McCune-Albright syndrome: Prevalence, etiologies, and clinical implications. <i>Bone</i> , 2021, 143, 115661.	1.4	6
7	Genotype-Phenotype Correlation in Fibrous Dysplasia/McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1482-1490.	1.8	7
8	A Cross-sectional Cohort Study of the Effects of <sc>FGF23</sc> Deficiency and Hyperphosphatemia on Dental Structures in Hyperphosphatemic Familial Tumoral Calcinosis. <i>JBMR Plus</i> , 2021, 5, e10470.	1.3	8
9	Hyperphosphatemic Familial Tumoral Calcinosis Hidden in Plain Sight for 73 Years: A Case Report. <i>Frontiers in Dental Medicine</i> , 2021, 2, .	0.5	0
10	Periorbital inflammation associated with craniofacial fibrous dysplasia: Report of three cases and review of the literature. <i>Bone</i> , 2021, 153, 116157.	1.4	4
11	Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gs Activation. <i>Endocrine Reviews</i> , 2020, 41, 345-370.	8.9	87
12	Diseases resulting from defects in the G protein Gs. , 2020, , 1431-1461.		0
13	Tumor-induced osteomalacia. , 2020, , 1539-1552.		1
14	Approach to patients with hypophosphataemia. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 163-174.	5.5	44
15	A rare cause of atraumatic fractures: case series of four patients with tumor-induced osteomalacia. <i>Clinical Diabetes and Endocrinology</i> , 2020, 6, 12.	1.3	3
16	Utility of Optical Coherence Tomography in the Diagnosis and Management of Optic Neuropathy in Patients with Fibrous Dysplasia. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 2199-2210.	3.1	4
17	Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia. <i>New England Journal of Medicine</i> , 2020, 383, 1387-1389.	13.9	27
18	Denosumab for Fibrous Dysplasia: Promising, but Questions Remain. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4179-e4180.	1.8	14

#	ARTICLE	IF	CITATIONS
19	Successful Intravascular Treatment of an Intraosseous Arteriovenous Fistula in Fibrous Dysplasia. <i>Calcified Tissue International</i> , 2020, 107, 195-200.	1.5	4
20	PET Imaging of Phosphodiesterase-4 Identifies Affected Dysplastic Bone in McCune-Albright Syndrome, a Genetic Mosaic Disorder. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1672-1677.	2.8	6
21	C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 315-321.	3.1	9
22	Burosumab for Tumor-Induced Osteomalacia: Not Enough of a Good Thing. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 2453-2454.	3.1	4
23	PTH and FGF23 Exert Interdependent Effects on Renal Phosphate Handling: Evidence From Patients With Hypoparathyroidism and Hyperphosphatemic Familial Tumoral Calcinosis Treated With Synthetic Human PTH 1-34. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 179-184.	3.1	10
24	PTH 1-34 Replacement Therapy Has Minimal Effect on Quality of Life in Patients With Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 68-77.	3.1	5
25	First in Mice: RANKL Neutralization in Fibrous Dysplasia. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2169-2170.	3.1	3
26	¹⁸ F-NaF PET/CT IMAGING IN FIBROUS DYSPLASIA OF BONE. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1619-1631.	3.1	28
27	Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic NPS795 (SHP635). <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1609-1618.	3.1	30
28	Gynecologic and reproductive outcomes in fibrous dysplasia/McCune-Albright syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 90.	1.2	15
29	Hypoparathyroidism. <i>New England Journal of Medicine</i> , 2019, 380, 1738-1747.	13.9	84
30	The Clinical Spectrum of McCune-Albright Syndrome and Its Management. <i>Hormone Research in Paediatrics</i> , 2019, 92, 347-356.	0.8	49
31	Neonatal McCune-Albright Syndrome: A Unique Syndromic Profile With an Unfavorable Outcome. <i>JBMR Plus</i> , 2019, 3, e10134.	1.3	12
32	Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 653-660.	3.1	58
33	Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 290-294.	3.1	65
34	Bone Matrix Mineralization in Patients With Gain-of-Function Calcium-Sensing Receptor Mutations Is Distinctly Different From that in Postsurgical Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 661-668.	3.1	4
35	Association of Hearing Loss and Otologic Outcomes With Fibrous Dysplasia. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 102.	1.2	35
36	Growth hormone/Insulin-like growth factor 1 axis hyperactivity on bone fibrous dysplasia in McCune-Albright Syndrome. <i>Clinical Endocrinology</i> , 2018, 89, 56-64.	1.2	21

#	ARTICLE	IF	CITATIONS
37	Scoliosis in Fibrous Dysplasia/McCune-Albright Syndrome: Factors Associated With Curve Progression and Effects of Bisphosphonates. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1641-1648.	3.1	29
38	Expression of an active G1± mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E428-E437.	3.3	43
39	Increased Risk of Breast Cancer at a Young Age in Women with Fibrous Dysplasia. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 84-90.	3.1	39
40	Bone marrow failure and extramedullary hematopoiesis in McCune-Albright syndrome. <i>Osteoporosis International</i> , 2018, 29, 237-241.	1.3	5
41	Chiari I Malformation and Basilar Invagination in Fibrous Dysplasia: Prevalence, Mechanisms, and Clinical Implications. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1990-1998.	3.1	30
42	Mosaic Effects of Growth Hormone on Fibrous Dysplasia of Bone. <i>New England Journal of Medicine</i> , 2018, 379, 1964-1965.	13.9	8
43	Fibrous dysplasia for radiologists: beyond ground glass bone matrix. <i>Insights Into Imaging</i> , 2018, 9, 1035-1056.	1.6	117
44	Clinical and Radiographic Gastrointestinal Abnormalities in McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4293-4303.	1.8	15
45	Multilineage <i>ACTB</i> mutation in a patient with fibroosseous maxillary lesion and pilocytic astrocytoma. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2037-2040.	0.7	2
46	Letter to the Editor Regarding "Optical Coherence Tomography in the Management of Skull Base Fibrous Dysplasia with Optic Nerve Involvement". <i>World Neurosurgery</i> , 2018, 114, 427-428.	0.7	0
47	Gs1±, Pseudohypoparathyroidism, Fibrous Dysplasia, and McCune-Albright Syndrome. , 2018, , 637-653.		0
48	Hypocitraturia Is an Untoward Side Effect of Synthetic Human Parathyroid Hormone (hPTH) 1-34 Therapy in Hypoparathyroidism That May Increase Renal Morbidity. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1741-1747.	3.1	20
49	Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies. <i>Journal of Clinical Investigation</i> , 2018, 128, 5368-5373.	3.9	27
50	Patients with McCune-Albright syndrome have a broad spectrum of abnormalities in the gastrointestinal tract and pancreas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 391-400.	1.4	39
51	Octreotide Is Ineffective in Treating Tumor-Induced Osteomalacia: Results of a Short-Term Therapy. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1667-1671.	3.1	14
52	Tumor-induced osteomalacia. <i>Bone Reports</i> , 2017, 7, 90-97.	0.2	93
53	Multimodality Image-Guided Cryoablation for Inoperable Tumor-Induced Osteomalacia. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2248-2256.	3.1	28
54	Tumour-induced osteomalacia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17044.	18.1	204

#	ARTICLE	IF	CITATIONS
55	Celecoxib treatment of fibrous dysplasia (FD) in a human FD cell line and FD-like lesions in mice with protein kinase A (PKA) defects. <i>Molecular and Cellular Endocrinology</i> , 2017, 439, 165-174.	1.6	5
56	Surgical Management of Polyostotic Craniofacial Fibrous Dysplasia: Long-Term Outcomes and Predictors for Postoperative Regrowth. <i>Plastic and Reconstructive Surgery</i> , 2016, 137, 1833-1839.	0.7	58
57	Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1845-1854.	3.1	67
58	The hypoxia-inducible factor-1 α activates ectopic production of fibroblast growth factor 23 in tumor-induced osteomalacia. <i>Bone Research</i> , 2016, 4, 16011.	5.4	54
59	Fibrous Dysplasia and Medication-Related Osteonecrosis of the Jaw. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016, 74, 1983-1999.	0.5	30
60	Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives. <i>Current Osteoporosis Reports</i> , 2016, 14, 178-186.	1.5	107
61	1,25-Dihydroxyvitamin D as Monotherapy for XLH: Back to the Future?. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 925-928.	3.1	4
62	Long-term outcomes of letrozole treatment for precocious puberty in girls with McCune-Albright syndrome. <i>European Journal of Endocrinology</i> , 2016, 175, 477-483.	1.9	49
63	Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. <i>Osteoporosis International</i> , 2016, 27, 3615-3626.	1.3	48
64	⁶⁸ Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3575-3581.	1.8	111
65	Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. <i>Modern Pathology</i> , 2016, 29, 1335-1346.	2.9	139
66	Fibrous Dysplasia. <i>Plastic and Reconstructive Surgery</i> , 2016, 137, 1060e-1061e.	0.7	2
67	Bone-Grafting in Polyostotic Fibrous Dysplasia. <i>Journal of Bone and Joint Surgery - Series A</i> , 2016, 98, 211-219.	1.4	48
68	Epidemiology and Diagnosis of Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2284-2299.	1.8	230
69	Transient Increased Calcium and Calcitriol Requirements After Discontinuation of Human Synthetic Parathyroid Hormone 1-34 (hPTH 1-34) Replacement Therapy in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 2112-2118.	3.1	28
70	Impaired osteoblast and osteoclast function characterize the osteoporosis of Snyder - Robinson syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 27.	1.2	27
71	X-linked acro-gigantism syndrome: clinical profile and therapeutic responses. <i>Endocrine-Related Cancer</i> , 2015, 22, 353-367.	1.6	151
72	The PTH-Vitamin D-FGF23 axis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2015, 16, 165-174.	2.6	128

#	ARTICLE	IF	CITATIONS
73	A Randomized, Double Blind, Placebo-Controlled Trial of Alendronate Treatment for Fibrous Dysplasia of Bone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4133-4140.	1.8	107
74	Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. <i>Human Molecular Genetics</i> , 2014, 23, 397-407.	1.4	112
75	Partnerships in rare disorders. <i>Journal of the American Dental Association</i> , 2014, 145, 694-695.	0.7	3
76	Oral Pigmentation in McCune-Albright Syndrome. <i>JAMA Dermatology</i> , 2014, 150, 760.	2.0	25
77	Radiographic Classification of Coronal Plane Femoral Deformities in Polyostotic Fibrous Dysplasia. <i>Clinical Orthopaedics and Related Research</i> , 2014, 472, 1558-1567.	0.7	50
78	Effects of Denosumab Treatment and Discontinuation on Human Growth Plates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 891-897.	1.8	57
79	RAS in FGF23: Another Piece in the Puzzle. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 63-66.	1.8	6
80	Acromegaly and McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1955-1969.	1.8	149
81	Disease severity and functional factors associated with walking performance in polyostotic fibrous dysplasia. <i>Bone</i> , 2014, 60, 41-47.	1.4	22
82	A High Throughput Screening Assay System for the Identification of Small Molecule Inhibitors of gsp. <i>PLoS ONE</i> , 2014, 9, e90766.	1.1	16
83	Fibrous Dysplasia and Fibroblast Growth Factor-23 Regulation. <i>Current Osteoporosis Reports</i> , 2013, 11, 65-71.	1.5	32
84	Dental perspectives in fibrous dysplasia and McCune-Albright syndrome. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2013, 116, e149-e155.	0.2	46
85	Optic Neuropathy in McCune-Albright Syndrome: Effects of Early Diagnosis and Treatment of Growth Hormone Excess. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E126-E134.	1.8	64
86	Successful Treatment of Tumor-Induced Osteomalacia due to an Intracranial Tumor by Fractionated Stereotactic Radiotherapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4267-4272.	1.8	41
87	Sinonasal Disease in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome. <i>Laryngoscope</i> , 2013, 123, 823-828.	1.1	19
88	Gs \pm , Pseudohypoparathyroidism, Fibrous Dysplasia, and McCune-Albright Syndrome. , 2013, , 425-440.		3
89	Tumor localization and biochemical response to cure in tumor-induced osteomalacia. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1386-1398.	3.1	108
90	Characterization and Management of Testicular Pathology in McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1782-E1790.	1.8	72

#	ARTICLE	IF	CITATIONS
91	Somatic <i>GNAS</i> Mutation Causes Widespread and Diffuse Pituitary Disease in Acromegalic Patients with McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2404-2413.	1.8	77
92	Fibroblast growth factor 23: state of the field and future directions. <i>Trends in Endocrinology and Metabolism</i> , 2012, 23, 610-618.	3.1	107
93	Mechanism of FGF23 processing in fibrous dysplasia. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1132-1141.	3.1	106
94	Denosumab treatment for fibrous dysplasia. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1462-1470.	3.1	202
95	Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1811-1820.	3.1	71
96	McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia. <i>Orphanet Journal of Rare Diseases</i> , 2012, 7, S4.	1.2	199
97	Surgery versus Watchful Waiting in Patients with Craniofacial Fibrous Dysplasia – a Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e25179.	1.1	71
98	Wnt/ β -catenin signaling is differentially regulated by G α proteins and contributes to fibrous dysplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20101-20106.	3.3	92
99	Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1295-1302.	3.1	110
100	Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 2317-2337.	3.1	485
101	The Importance of Whole Body Imaging in Tumor-Induced Osteomalacia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 3599-3600.	1.8	46
102	Case 33-2011. <i>New England Journal of Medicine</i> , 2011, 365, 1625-1635.	13.9	33
103	Tumor-induced osteomalacia. <i>Endocrine-Related Cancer</i> , 2011, 18, R53-R77.	1.6	339
104	Cushing Syndrome in the McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1508-1515.	1.8	113
105	En bloc spondylectomy for treatment of tumor-induced osteomalacia. <i>Journal of Neurosurgery: Spine</i> , 2009, 11, 600-604.	0.9	24
106	A case of familial tumoral calcinosis/hyperostosis – hyperphosphatemia syndrome due to a compound heterozygous mutation in <i>GALNT3</i> demonstrating new phenotypic features. <i>Osteoporosis International</i> , 2009, 20, 1273-1278.	1.3	44
107	Clinical Vignette: PTH(1-34) Replacement Therapy in a Child With Hypoparathyroidism Caused by a Sporadic Calcium Receptor Mutation. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 964-973.	3.1	72
108	Pain in fibrous dysplasia of bone: age-related changes and the anatomical distribution of skeletal lesions. <i>Osteoporosis International</i> , 2008, 19, 57-63.	1.3	100

#	ARTICLE	IF	CITATIONS
109	Age-Dependent Demise of <i>GNAS</i> -Mutated Skeletal Stem Cells and "Normalization" of Fibrous Dysplasia of Bone. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1731-1740.	3.1	119
110	McCune-Albright syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2008, 3, 12.	1.2	367
111	The Role of Type 1 and Type 2 5 α -Deiodinase in the Pathophysiology of the 3,5,3 α -Triiodothyronine Toxicosis of McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2383-2389.	1.8	52
112	Diseases Resulting from Defects in the G Protein Gs α . , 2008, , 1453-1477.		2
113	Determination of the Elimination Half-Life of Fibroblast Growth Factor-23. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2374-2377.	1.8	133
114	Letrozole Treatment of Precocious Puberty in Girls with the McCune-Albright Syndrome: A Pilot Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2100-2106.	1.8	93
115	<i>GNAS</i> transcripts in skeletal progenitors: evidence for random asymmetric allelic expression of Gs α . <i>Human Molecular Genetics</i> , 2007, 16, 1921-1930.	1.4	35
116	Cinacalcet in the Management of Tumor-Induced Osteomalacia. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 931-937.	3.1	126
117	Onset, Progression, and Plateau of Skeletal Lesions in Fibrous Dysplasia and the Relationship to Functional Outcome. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1468-1474.	3.1	122
118	Current approach to fibrous dysplasia of bone and McCune-Albright syndrome. <i>Journal of Children's Orthopaedics</i> , 2007, 1, 3-17.	0.4	82
119	Spectrum and Natural History of Fibrous Dysplasia of Bone. <i>Journal of Bone and Mineral Research</i> , 2006, 21, P99-P104.	3.1	53
120	Skeletal site-specific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. <i>Bone</i> , 2006, 38, 758-768.	1.4	318
121	LONG-TERM OUTCOME OF OPTIC NERVE ENCASEMENT AND OPTIC NERVE DECOMPRESSION IN PATIENTS WITH FIBROUS DYSPLASIA. <i>Neurosurgery</i> , 2006, 59, 1011-1018.	0.6	81
122	Pegvisomant for the Treatment of <i>gsp</i> -Mediated Growth Hormone Excess in Patients with McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2960-2966.	1.8	48
123	The Correlation of Specific Orthopaedic Features of Polyostotic Fibrous Dysplasia with Functional Outcome Scores in Children. <i>Journal of Bone and Joint Surgery - Series A</i> , 2006, 88, 818-823.	1.4	21
124	Citrate Effects and Bone Mineral Density (BMD) in Serial Long-Term Apheresis Donors.. <i>Blood</i> , 2006, 108, 953-953.	0.6	1
125	THE CORRELATION OF SPECIFIC ORTHOPAEDIC FEATURES OF POLYOSTOTIC FIBROUS DYSPLASIA WITH FUNCTIONAL OUTCOME SCORES IN CHILDREN. <i>Journal of Bone and Joint Surgery - Series A</i> , 2006, 88, 818-823.	1.4	1
126	Fibroblast Growth Factor-23 Is Regulated by 1 α ,25-Dihydroxyvitamin D. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1944-1950.	3.1	92

#	ARTICLE	IF	CITATIONS
127	Physical function is impaired but quality of life preserved in patients with fibrous dysplasia of bone. <i>Bone</i> , 2005, 37, 388-394.	1.4	42
128	A novel technique based on a PNA hybridization probe and FRET principle for quantification of mutant genotype in fibrous dysplasia/McCune-Albright syndrome. <i>Nucleic Acids Research</i> , 2004, 32, e63-e63.	6.5	42
129	An Instrument to Measure Skeletal Burden and Predict Functional Outcome in Fibrous Dysplasia of Bone. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 219-226.	3.1	107
130	Fibrous Dysplasia in the Spine. <i>Journal of Bone and Joint Surgery - Series A</i> , 2004, 86, 531-537.	1.4	96
131	Fibrous dysplasia in the spine: prevalence of lesions and association with scoliosis. <i>Journal of Bone and Joint Surgery - Series A</i> , 2004, 86, 531-7.	1.4	31
132	Fracture Incidence in Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome. <i>Journal of Bone and Mineral Research</i> , 2003, 19, 571-577.	3.1	136
133	Osteomalacic and Hyperparathyroid Changes in Fibrous Dysplasia Of Bone: Core Biopsy Studies and Clinical Correlations. <i>Journal of Bone and Mineral Research</i> , 2003, 18, 1235-1246.	3.1	87
134	Thyroid Carcinoma in the McCune-Albright Syndrome: Contributory Role of Activating Gs α Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4413-4417.	1.8	109
135	FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. <i>Journal of Clinical Investigation</i> , 2003, 112, 683-692.	3.9	567
136	Normal Vision despite Narrowing of the Optic Canal in Fibrous Dysplasia. <i>New England Journal of Medicine</i> , 2002, 347, 1670-1676.	13.9	183
137	Characterization of gsp-Mediated Growth Hormone Excess in the Context of McCune-Albright Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5104-5112.	1.8	145
138	Orthopedic Concerns in Children with Endocrine Disorders. <i>Journal of Pediatric Orthopaedics Part B</i> , 2002, 11, 183-191.	0.3	1
139	Ribbing disease: radiographic and biochemical characterization, lack of response to pamidronate. <i>Skeletal Radiology</i> , 2002, 31, 714-719.	1.2	32
140	Renal Phosphate Wasting in Fibrous Dysplasia of Bone Is Part of a Generalized Renal Tubular Dysfunction Similar to That Seen in Tumor-Induced Osteomalacia. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 806-813.	3.1	165
141	McCune-Albright syndrome: new insights. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 1999, 6, 119-125.	0.6	42